Barclays
INFI

Barclays’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Barclays’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,600
Closed -$86K – 7685
2014
Q3 		$86K Sell
6,600
-103,800
-94% -$1.24M ﹤0.01% 5445
2014
Q2 		$1.32M Hold
110,400
– – ﹤0.01% 3054
2014
Q1 		$1.21M Buy
110,400
+100,400
+1,004% +$1.35M ﹤0.01% 3041
2013
Q4 		$130K Sell
10,000
-180,000
-95% -$2.54M ﹤0.01% 5415
2013
Q3 		$3.23M Hold
190,000
– – ﹤0.01% 2094
2013
Q2 		$3.08M Buy
+190,000
New +$5.88M ﹤0.01% 2069

Other funds holding INFI

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays's INFI Position: Q1 2023 in Review

Barclays sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q1 2023, closing a stake of 359 shares — an estimated $199 sold.

Barclays first reported a position in INFI in Q2 2013 and held it in 33 quarters. The position peaked at $3.98M in Q3 2014. 53 funds tracked by Wall St. Rank hold INFI as of Q1 2023.

  • Barclays reported no remaining Infinity Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
  • Barclays sold 359 Infinity Pharmaceuticals, Inc. shares in Q1 2023, an estimated $199.
  • Barclays first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 33 quarters.
  • Barclays's Infinity Pharmaceuticals, Inc. position peaked at $3.98M in Q3 2014.
  • 53 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q1 2023.

Based on Barclays's 13F filing for Q1 2023, filed 4 May 2023.